Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey
Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated chil...
Gespeichert in:
Veröffentlicht in: | International journal of infectious diseases 2012-05, Vol.16 (5), p.e354-e357 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | e357 |
---|---|
container_issue | 5 |
container_start_page | e354 |
container_title | International journal of infectious diseases |
container_volume | 16 |
creator | Yüksel, Nurullah Beyazova, Ufuk Balci, Işil Fidan Aksakal, Fatma Nur Çamurdan, Aysu Duyan Sahin, Figen Rota, Seyyal |
description | Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP. |
doi_str_mv | 10.1016/j.ijid.2012.01.005 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1001953768</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1201971212000380</els_id><sourcerecordid>1001953768</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</originalsourceid><addsrcrecordid>eNp9UktuFDEQbSEQCYELsEBespnBdv_cEkJCUSCRIrEgrC23XZ1x020P_kw0WXEHjsUtOAnVzIQFC1Zl6X1cVa-K4iWja0ZZ82Zc29GaNaeMrylbU1o_Kk6ZaMWqrBl7jG-EVl3L-EnxLMaRUlo1jXhanHBeipZV1Wnx82qes_O34Ky2aU_8QBS5VDD77cZOORLrhimDu1dA0n4LpP_1_UeCpBxi2rsx36oEZKe0tg7I3QYcUWa2zsYEAQyJsFUBKRN6B3RD0dwj1TxoIhkQ2AY7q7AndmnH3qtkvVvY6c4v30TQOdkdEPcHUROJegMmT7B0SG5y-Ar758WTQU0RXhzrWfHlw8XN-eXq-tPHq_P31ytd1XVacUNr6EuqOR_UYAxvaiOYqDg1ojedMVp3XOtSsNJUrWjboam1GjpRdX3X6KY8K14ffLfBf8sQk5xt1DBNyoHPUTJKWVeXbSOQyg9UHXyMAQZ5HBRJcglRjnIJUS4hSsokhoiiV0f_3M9g_koeUkPC2wMBcMqdhSCjtuA0GBtAJ2m8_b__u3_kesLAtJpwiRBHnwNuGOeQETXy83JGyxVhpbQUtPwNcwLKbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1001953768</pqid></control><display><type>article</type><title>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Yüksel, Nurullah ; Beyazova, Ufuk ; Balci, Işil Fidan ; Aksakal, Fatma Nur ; Çamurdan, Aysu Duyan ; Sahin, Figen ; Rota, Seyyal</creator><creatorcontrib>Yüksel, Nurullah ; Beyazova, Ufuk ; Balci, Işil Fidan ; Aksakal, Fatma Nur ; Çamurdan, Aysu Duyan ; Sahin, Figen ; Rota, Seyyal</creatorcontrib><description>Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.</description><identifier>ISSN: 1201-9712</identifier><identifier>EISSN: 1878-3511</identifier><identifier>DOI: 10.1016/j.ijid.2012.01.005</identifier><identifier>PMID: 22387144</identifier><language>eng</language><publisher>Canada: Elsevier Ltd</publisher><subject><![CDATA[Anti-PRP antibodies ; Antibodies, Bacterial - blood ; Diphtheria Toxoid - administration & dosage ; Haemophilus Infections - prevention & control ; Haemophilus influenzae type b ; Haemophilus influenzae type b - immunology ; Haemophilus Vaccines - administration & dosage ; Haemophilus Vaccines - immunology ; Humans ; Immunogenicity ; Infant ; Infectious Disease ; Mass Vaccination ; Pertussis Vaccine - administration & dosage ; Poliovirus Vaccine, Inactivated - administration & dosage ; Polysaccharides - immunology ; Population Surveillance ; Pulmonary/Respiratory ; Tetanus Toxoid - administration & dosage ; Turkey ; Vaccination schedule ; Vaccines, Acellular - administration & dosage ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - immunology]]></subject><ispartof>International journal of infectious diseases, 2012-05, Vol.16 (5), p.e354-e357</ispartof><rights>International Society for Infectious Diseases</rights><rights>2012 International Society for Infectious Diseases</rights><rights>Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</citedby><cites>FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijid.2012.01.005$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,778,782,862,3539,27913,27914,45984</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22387144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yüksel, Nurullah</creatorcontrib><creatorcontrib>Beyazova, Ufuk</creatorcontrib><creatorcontrib>Balci, Işil Fidan</creatorcontrib><creatorcontrib>Aksakal, Fatma Nur</creatorcontrib><creatorcontrib>Çamurdan, Aysu Duyan</creatorcontrib><creatorcontrib>Sahin, Figen</creatorcontrib><creatorcontrib>Rota, Seyyal</creatorcontrib><title>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</title><title>International journal of infectious diseases</title><addtitle>Int J Infect Dis</addtitle><description>Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.</description><subject>Anti-PRP antibodies</subject><subject>Antibodies, Bacterial - blood</subject><subject>Diphtheria Toxoid - administration & dosage</subject><subject>Haemophilus Infections - prevention & control</subject><subject>Haemophilus influenzae type b</subject><subject>Haemophilus influenzae type b - immunology</subject><subject>Haemophilus Vaccines - administration & dosage</subject><subject>Haemophilus Vaccines - immunology</subject><subject>Humans</subject><subject>Immunogenicity</subject><subject>Infant</subject><subject>Infectious Disease</subject><subject>Mass Vaccination</subject><subject>Pertussis Vaccine - administration & dosage</subject><subject>Poliovirus Vaccine, Inactivated - administration & dosage</subject><subject>Polysaccharides - immunology</subject><subject>Population Surveillance</subject><subject>Pulmonary/Respiratory</subject><subject>Tetanus Toxoid - administration & dosage</subject><subject>Turkey</subject><subject>Vaccination schedule</subject><subject>Vaccines, Acellular - administration & dosage</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - immunology</subject><issn>1201-9712</issn><issn>1878-3511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UktuFDEQbSEQCYELsEBespnBdv_cEkJCUSCRIrEgrC23XZ1x020P_kw0WXEHjsUtOAnVzIQFC1Zl6X1cVa-K4iWja0ZZ82Zc29GaNaeMrylbU1o_Kk6ZaMWqrBl7jG-EVl3L-EnxLMaRUlo1jXhanHBeipZV1Wnx82qes_O34Ky2aU_8QBS5VDD77cZOORLrhimDu1dA0n4LpP_1_UeCpBxi2rsx36oEZKe0tg7I3QYcUWa2zsYEAQyJsFUBKRN6B3RD0dwj1TxoIhkQ2AY7q7AndmnH3qtkvVvY6c4v30TQOdkdEPcHUROJegMmT7B0SG5y-Ar758WTQU0RXhzrWfHlw8XN-eXq-tPHq_P31ytd1XVacUNr6EuqOR_UYAxvaiOYqDg1ojedMVp3XOtSsNJUrWjboam1GjpRdX3X6KY8K14ffLfBf8sQk5xt1DBNyoHPUTJKWVeXbSOQyg9UHXyMAQZ5HBRJcglRjnIJUS4hSsokhoiiV0f_3M9g_koeUkPC2wMBcMqdhSCjtuA0GBtAJ2m8_b__u3_kesLAtJpwiRBHnwNuGOeQETXy83JGyxVhpbQUtPwNcwLKbg</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Yüksel, Nurullah</creator><creator>Beyazova, Ufuk</creator><creator>Balci, Işil Fidan</creator><creator>Aksakal, Fatma Nur</creator><creator>Çamurdan, Aysu Duyan</creator><creator>Sahin, Figen</creator><creator>Rota, Seyyal</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</title><author>Yüksel, Nurullah ; Beyazova, Ufuk ; Balci, Işil Fidan ; Aksakal, Fatma Nur ; Çamurdan, Aysu Duyan ; Sahin, Figen ; Rota, Seyyal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-2d05eb30c22fafdd265d818420d8bd9ddcc92cc3813d47877f65caf9849b96c63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-PRP antibodies</topic><topic>Antibodies, Bacterial - blood</topic><topic>Diphtheria Toxoid - administration & dosage</topic><topic>Haemophilus Infections - prevention & control</topic><topic>Haemophilus influenzae type b</topic><topic>Haemophilus influenzae type b - immunology</topic><topic>Haemophilus Vaccines - administration & dosage</topic><topic>Haemophilus Vaccines - immunology</topic><topic>Humans</topic><topic>Immunogenicity</topic><topic>Infant</topic><topic>Infectious Disease</topic><topic>Mass Vaccination</topic><topic>Pertussis Vaccine - administration & dosage</topic><topic>Poliovirus Vaccine, Inactivated - administration & dosage</topic><topic>Polysaccharides - immunology</topic><topic>Population Surveillance</topic><topic>Pulmonary/Respiratory</topic><topic>Tetanus Toxoid - administration & dosage</topic><topic>Turkey</topic><topic>Vaccination schedule</topic><topic>Vaccines, Acellular - administration & dosage</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yüksel, Nurullah</creatorcontrib><creatorcontrib>Beyazova, Ufuk</creatorcontrib><creatorcontrib>Balci, Işil Fidan</creatorcontrib><creatorcontrib>Aksakal, Fatma Nur</creatorcontrib><creatorcontrib>Çamurdan, Aysu Duyan</creatorcontrib><creatorcontrib>Sahin, Figen</creatorcontrib><creatorcontrib>Rota, Seyyal</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yüksel, Nurullah</au><au>Beyazova, Ufuk</au><au>Balci, Işil Fidan</au><au>Aksakal, Fatma Nur</au><au>Çamurdan, Aysu Duyan</au><au>Sahin, Figen</au><au>Rota, Seyyal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey</atitle><jtitle>International journal of infectious diseases</jtitle><addtitle>Int J Infect Dis</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>16</volume><issue>5</issue><spage>e354</spage><epage>e357</epage><pages>e354-e357</pages><issn>1201-9712</issn><eissn>1878-3511</eissn><abstract>Summary Background In Turkey, the Haemophilus influenzae type b–tetanus toxoid conjugate vaccine (Hib) was replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in infants vaccinated with these different schedules. Methods Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and Hib for the first one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series. Results Anti-polyribosylribitol phosphate (anti-PRP) titers ≥0.15 μg/ml were similar in groups 1, 2, and 3. However, in group 1, who received all the vaccines at separate sites, ≥ l.0 μg/ml long-lasting antibody titers and anti-PRP geometric mean titers were higher ( p = 0.001). Conclusion This study showed that even one dose administered in combination with other vaccines in a primary series decreased the level of anti-PRP.</abstract><cop>Canada</cop><pub>Elsevier Ltd</pub><pmid>22387144</pmid><doi>10.1016/j.ijid.2012.01.005</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1201-9712 |
ispartof | International journal of infectious diseases, 2012-05, Vol.16 (5), p.e354-e357 |
issn | 1201-9712 1878-3511 |
language | eng |
recordid | cdi_proquest_miscellaneous_1001953768 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ScienceDirect Journals (5 years ago - present) |
subjects | Anti-PRP antibodies Antibodies, Bacterial - blood Diphtheria Toxoid - administration & dosage Haemophilus Infections - prevention & control Haemophilus influenzae type b Haemophilus influenzae type b - immunology Haemophilus Vaccines - administration & dosage Haemophilus Vaccines - immunology Humans Immunogenicity Infant Infectious Disease Mass Vaccination Pertussis Vaccine - administration & dosage Poliovirus Vaccine, Inactivated - administration & dosage Polysaccharides - immunology Population Surveillance Pulmonary/Respiratory Tetanus Toxoid - administration & dosage Turkey Vaccination schedule Vaccines, Acellular - administration & dosage Vaccines, Combined - administration & dosage Vaccines, Combined - immunology |
title | Immunogenicity of a Haemophilus influenzae type b–tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20a%20Haemophilus%20influenzae%20type%20b%E2%80%93tetanus%20conjugate%20vaccine%20when%20administered%20separately%20or%20in%20combined%20vaccines%20for%20primary%20immunization%20in%20two%20consecutive%20national%20schedules%20in%20Turkey&rft.jtitle=International%20journal%20of%20infectious%20diseases&rft.au=Y%C3%BCksel,%20Nurullah&rft.date=2012-05-01&rft.volume=16&rft.issue=5&rft.spage=e354&rft.epage=e357&rft.pages=e354-e357&rft.issn=1201-9712&rft.eissn=1878-3511&rft_id=info:doi/10.1016/j.ijid.2012.01.005&rft_dat=%3Cproquest_cross%3E1001953768%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1001953768&rft_id=info:pmid/22387144&rft_els_id=S1201971212000380&rfr_iscdi=true |